Patents by Inventor Robert Patrick Hof
Robert Patrick Hof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9670520Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: GrantFiled: May 2, 2016Date of Patent: June 6, 2017Assignee: Patheon Holdings | B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Publication number: 20170057987Abstract: The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions.Type: ApplicationFiled: April 5, 2016Publication date: March 2, 2017Inventors: Johannes Gernardus Mathias Marie Van Bree, Everardus Joannes Peter Maria Schenkelaars, Jouwert Anne Turkstra, Maria Aldegonda Jacoba Kriek, Robert Patrick Hof, Wilhelmus Martinus Maria Schaaper
-
Patent number: 9469865Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cells culture comprising the cells, the biological substance and the cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: GrantFiled: February 7, 2014Date of Patent: October 18, 2016Assignee: DPX Holdings B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Publication number: 20160265017Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: May 2, 2016Publication date: September 15, 2016Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Patent number: 9327020Abstract: The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions.Type: GrantFiled: June 3, 2011Date of Patent: May 3, 2016Assignee: Immunovo B.V.Inventors: Johannes Gernardus Mathias Marie Van Bree, Everardus Joannes Peter Maria Schenkelaars, Jouwert Anne Turkstra, Maria Aldegonda Jacoba Kriek, Robert Patrick Hof, Wilhelmus Martinus Maria Schaaper
-
Publication number: 20130273082Abstract: The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions.Type: ApplicationFiled: June 3, 2011Publication date: October 17, 2013Applicant: IMMUNOVO B.V.Inventors: Johannes Gernardus Mathias Marie Van Bree, Everardus Joannes Peter Maria Schenkelaars, Jouwert Anne Turkstra, Maria Aldegonda Jacoba Kriek, Robert Patrick Hof, Wilhelmus Martinus Maria Schaaper
-
Publication number: 20120149107Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: February 15, 2012Publication date: June 14, 2012Applicant: DSM IP ASSETS B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Publication number: 20120149063Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: February 13, 2012Publication date: June 14, 2012Applicant: DSM IP ASSETS B.V.Inventors: Gerben Meile ZIJLSTRA, Robert Patrick HOF, Jacobs SCHILDER
-
Publication number: 20120064623Abstract: The invention relates to a process for the culturing of cells, preferably El-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: October 25, 2011Publication date: March 15, 2012Applicant: DSM IP ASSETS B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Patent number: 8119368Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: GrantFiled: July 4, 2007Date of Patent: February 21, 2012Assignee: DSM IP Assets B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Patent number: 7718812Abstract: The invention relates to a process for the conversion of group X in a 2-(6-substituted)-1,3-dioxane-4yl) acetic acid derivative according to formula 2 into a group OY in the presence of a phase transfer catalyst and an oxylating agent, by using as a phase transfer catalyst a quarternary phosphonium ion and by using as an oxylating agent an OY-ion. X stands for a halogen and R1, R2 and R3 are each independently a C1–4 alkylgroup or R1 and R2 together with the C-atom to which they are bound form a 5- or 6-membered cycloalkyl; Y stands for RA-CO— or for RB—SO2- with RA, RB are chosen from the group of alkyl or aryl with 1–12 C-atoms.Type: GrantFiled: December 9, 2002Date of Patent: May 18, 2010Assignee: AstraZeneca UK LimitedInventor: Robert Patrick Hof
-
Publication number: 20100075413Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: July 4, 2007Publication date: March 25, 2010Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Patent number: 6846955Abstract: The invention relates to a process for racemising an enantiomer-enriched Schiff base of a primary amino acid amide with a strong base that is chemically reactive towards water. The reaction is conducted in an organic solvent. Preferably a metal alkoxide, a metal alkyl, a metal amide, or a metal hydride, in particular a metal alkoxide is applied as the strong base. As the Schiff base preferably N-benzylidene primary amino acid amide is used, with the primary amino acid amide preferably being derived from an aliphatic primary amino acid amide, for example tertiary-leucine amide. As organic solvent use is preferably made of an aromatic hydrocarbon, a cyclic, aliphatic hydrocarbon or a ether, in particular an aromatic hydrocarbon is applied. The invention may also be applied for the racemisation of an enantiomer-enriched primary amino acid amide.Type: GrantFiled: June 22, 2001Date of Patent: January 25, 2005Assignee: DSM N.V.Inventors: Robert Patrick Hof, Petrus Johannes Hermsen, Ronus de Bode
-
Patent number: 6586634Abstract: Process for the preparation of (1S,2R)-1-amino-2-indanol-(R,R)-tartrate methanol solvate, in which in a solvent a mixture of enantiomers of cis-1-amino-2-indanol reacts at an elevated temperature with (R,R)-tartaric acid and methanol and in which optically enriched (1S,2R)-1-amino-2-indanol-(R,R)-tartrate methanol solvate crystallizes out, after which the crystals are recovered, the recovery taking place at a temperature between 10 and 50° C. in the presence of 0-20 wt. % water relative to the amount of methanol plus solvent, on the understanding that if the reaction mixture is essentially free from water the recovery substantially takes place at a temperature between 30 and 50° C. Preferably the reactants are at least in part contacted with each other at an elevated temperature and only methanol is used as solvent. Preferably the amount of (1S,2R)-1-amino-2-indanol applied is between 0.02 and 0.1 g per ml of solvent.Type: GrantFiled: June 12, 1998Date of Patent: July 1, 2003Assignee: DSM N.V.Inventor: Robert Patrick Hof
-
Publication number: 20010056209Abstract: The invention relates to a process for racemising an enantiomer-enriched Schiff base of a primary amino acid amide with a strong base that is chemically reactive towards water. The reaction is conducted in an organic solvent. Preferably a metal alkoxide, a metal alkyl, a metal amide, or a metal hydride, in particular a metal alkoxide is applied as the strong base. As the Schiff base preferably N-benzylidene primary amino acid amide is used, with the primary amino acid amide preferably being derived from an aliphatic primary amino acid amide, for example tertiary-leucine amide. As organic solvent use is preferably made of an aromatic hydrocarbon, a cyclic, aliphatic hydrocarbon or a ether, in particular an aromatic hydrocarbon is applied. The invention may also be applied for the racemisation of an enantiomer-enriched primary amino acid amide.Type: ApplicationFiled: June 22, 2001Publication date: December 27, 2001Inventors: Robert Patrick Hof, Petrus Johannes Hermsen, Ronus De Bode